폐동맥 고혈압의 쥐 모델에서 우심실 기능의 종합적인 심초음파 평가

Executive Industry Relevance

Comprehensive echocardiographic assessment of right ventricular function in rat models of pulmonary arterial hypertension (PAH) enables robust evaluation of therapeutic efficacy and mechanistic de-risking in preclinical drug discovery. Standardized, quantitative imaging of RV structure and function supports predictive confidence at the target validation and lead optimization stages. This capability is critical for portfolio triage and advancing novel PAH therapies targeting right ventricular remodeling.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables quantitative interrogation of right ventricular remodeling in response to candidate therapeutics.
• Supports mechanistic de-risking by linking molecular interventions to functional cardiac outcomes.
• Facilitates functional target validation for pathways implicated in PAH progression.

Screening & Assay Development

• Provides standardized, reproducible imaging endpoints for preclinical efficacy screening.
• Delivers quantitative RV metrics (e.g., RVIDd, TAPSE) for cross-study comparability.
• Enables assay readiness for high-confidence compound evaluation in rodent models.

Translational & Preclinical Research

• Aligns preclinical cardiac imaging outputs with translational biomarker strategies in PAH.
• Supports continuity from discovery through preclinical validation by enabling longitudinal assessment of RV function.
• Reduces translational risk by providing disease-relevant functional endpoints.

Pipeline & Workflow Integration

This echocardiographic protocol integrates into the discovery-to-preclinical continuum for PAH, bridging early target validation with translational efficacy assessment.

• Discovery Biology: Quantitative RV imaging supports hypothesis testing and biological de-risking of novel targets.
• Screening: Standardized echocardiographic endpoints enable reproducible, scalable compound screening.
• Analytics: Provides objective measurements (e.g., RV dilation, TAPSE) for statistical comparison of treatment groups.
• Translational Research: Facilitates alignment of preclinical imaging with clinical cardiac biomarkers.
• Enterprise Reuse: Protocol can be adapted across PAH models and therapeutic modalities for consistent portfolio evaluation.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in PAH drug discovery.
• Operational Value: Enhances standardization, reproducibility, and scalability of preclinical cardiac assessments.
• Strategic Value: Informs go/no-go decisions and improves capital efficiency by enabling early functional readouts.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of PAH candidates targeting RV remodeling.

Implementation Considerations

• Requires specialized echocardiographic expertise for optimal RV imaging in rodents.
• Demands access to high-resolution ultrasound instrumentation and analytical software.
• Necessitates cross-team standardization of imaging protocols and data interpretation.
• Adaptation may be needed for different rodent models or disease severities.
• Technical challenges include achieving consistent RV-focused apical four chamber views.

Biopharma FAQs